Original scientific articleMulti-Modal Analgesic Strategy for Trauma: A Pragmatic Randomized Clinical Trial
Section snippets
Methods
The MAST trial was a pragmatic, randomized, comparative effectiveness trial comparing the original MMPR with the MAST MMPR. Its rationale and design have been detailed previously.9 IRB approval was obtained on March 2, 2018. Enrollment took place between April 2, 2018 and March 31, 2019.
Results
During the 12-month period, 3,385 patients were screened for eligibility; 34 eligible patients were not included; 1,634 were randomized; 73 were excluded after randomization (almost all because they refused consent or were ineligible for the trial); and 1,561 were included in the final analysis (Fig. 1). Median age of patients was 45 years (IQR 29 to 63 years), 68% were male, 29% were smokers, 12% reported a history of opioid use, and 24% had a positive urine drug screen on admission (Table 2).
Discussion
In this large, pragmatic randomized trial of adult injured patients, the use of the widely available MAST MMPR reduced inpatient opioid exposure and opioid prescribing at discharge with similar pain scores compared with our original MMPR. This finding was contrary to our hypothesis.
Overall, the MAST trial demonstrates that an opioid-minimizing acute pain strategy is effective and feasible in such injured patients. We enrolled patients admitted to the adult trauma service only. Because a large
Conclusions
The MAST MMPR reduced opioid exposure and discharge from the hospital with an opioid prescription while achieving similar pain control after trauma. These findings underscore the efficacy of opioid-minimizing strategies after trauma and the MAST MMPR has become usual practice for injured patients admitted to our trauma center.
Acknowledgment
The authors would like to acknowledge the residents and fellows of the Red Duke Trauma Center at Memorial Hermann Hospital-Texas Medical Center and the McGovern Medical School at UT Health for their active participation in and support of this trial. The authors would also like to acknowledge Peter V Killoran, MD, for his assistance obtaining electronic data and Michelle Sauer, PhD, ELS, for her editorial contributions.
References (35)
- et al.
Updates on multimodal analgesia for orthopedic surgery
Anesthesiol Clin
(2018) - et al.
Implementation of a multi-modal pain regimen to decrease inpatient opioid exposure after injury
Am J Surg
(2019) - et al.
Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials
J Clin Epidemiol
(2009) - et al.
Randomized, double-blind, placebo-controlled trial using lidocaine patch 5% in traumatic rib fractures
J Am Coll Surg
(2010) - et al.
A double-blind, randomized controlled trial of gabapentin vs. placebo for acute pain management in critically ill patients with rib fractures
Injury
(2018) - et al.
The impact of a curriculum on postoperative opioid prescribing for novice surgical trainees
Ame J Surg
(2019) - et al.
Risk factors and outcomes of chronic opioid use following trauma
Br J Surg
(2020) - et al.
Opioid exposure after injury in United States trauma centers: a prospective, multicenter observational study
J Trauma Acute Care Surg
(2020) - et al.
Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review
JAMA Surg
(2017) - et al.
How low can you go: achieving postoperative outpatient pain control without opioids
J Trauma Acute Care Surg
(2019)
Multimodal analgesia versus traditional opiate based analgesia after cardiac surgery, a randomized controlled trial
J Cardiothoracic Surg
Decreasing postoperative narcotics in reconstructive pelvic surgery: a randomized controlled trial
Am J Obstet Gynecol
Multi-modal Analgesic Strategies for Trauma (MAST): protocol for a pragmatic randomized trial
Trauma Surg Acute Care Open
An adapted Clavien-Dindo scoring system in trauma as a clinically meaningful nonmortality endpoint
J Trauma Acute Care Surg
National Trauma Data Bank. National Trauma Data Standard Data Dictionary: 2018 Admissions
Bayesian Approaches to Clinical Trials and Health-Care Evaluation
Cited by (0)
Disclosure Information: Dr Albarado receives speaker payments from Mallinckrodt Pharmaceuticals Speakers Bureau (Ofirmev).
Disclosures outside the scope of this work: Dr Holcomb is a paid consultant to PotentiaMetrics, Inc, Arsenal Medical, Inc, Cellphire, Inc, and CSL Limited; is a paid advisor to Spectrum Medical and Safeguard Medical, LLC; receives equity as a member of the Board of Directors for Decisio Health, QinFlow, and ZIBRIO; and receives royalty payments from UT Health as co-inventor of the Junctional Emergency Tourniquet Tool. Other authors have nothing to disclose.
Support: Dr Harvin was supported by the Center for Clinical and Translational Sciences, which is funded by NIH Clinical and Translational Award UL1 TR000371 and KL2 TR000370 from the National Center for Advancing Translational Sciences.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the NIH. This trial was also supported by a Learning Healthcare Award from the McGovern Medical School at University of Texas Health.
Members of the MAST Study Group who coauthored this article are listed in the Appendix.
Trial registration: ClinicalTrials.gov ID NCT03472469.